MENU
+Compare
GNPX
Stock ticker: NASDAQ
AS OF
Nov 24, 02:23 PM (EDT)
Price
$2.98
Change
-$0.02 (-0.67%)
Capitalization
6.81M

GNPX Genprex Inc. Forecast, Technical & Fundamental Analysis

Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes... Show more

GNPX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
a Summary for GNPX with price predictions
Nov 21, 2025

Momentum Indicator for GNPX turns negative, indicating new downward trend

GNPX saw its Momentum Indicator move below the 0 level on October 22, 2025. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 78 similar instances where the indicator turned negative. In of the 78 cases, the stock moved further down in the following days. The odds of a decline are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

GNPX moved below its 50-day moving average on October 22, 2025 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for GNPX crossed bearishly below the 50-day moving average on October 30, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where GNPX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for GNPX entered a downward trend on November 21, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 22 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

The Moving Average Convergence Divergence (MACD) for GNPX just turned positive on November 21, 2025. Looking at past instances where GNPX's MACD turned positive, the stock continued to rise in of 45 cases over the following month. The odds of a continued upward trend are .

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where GNPX advanced for three days, in of 205 cases, the price rose further within the following month. The odds of a continued upward trend are .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.873) is normal, around the industry mean (27.249). P/E Ratio (0.079) is within average values for comparable stocks, (51.596). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.881). Dividend Yield (0.000) settles around the average of (0.047) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (320.418).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. GNPX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GNPX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
GNPX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

a developer of molecular therapies for cancer treatment

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Pharmaceuticals Major
Address
3300 Bee Cave Road
Phone
+1 877 774-4679
Employees
26
Web
https://www.genprex.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
MNDR4.751.71
+56.25%
Mobile-health Network Solutions
LYTS18.140.72
+4.13%
LSI Industries
SW33.780.99
+3.02%
Smurfit WestRock plc
NATL35.610.87
+2.50%
NCR Atleos Corp
HYPR1.050.02
+2.44%
Hyperfine

GNPX and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, GNPX has been loosely correlated with OMER. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if GNPX jumps, then OMER could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GNPX
1D Price
Change %
GNPX100%
-5.06%
OMER - GNPX
49%
Loosely correlated
+7.78%
TOVX - GNPX
48%
Loosely correlated
+0.79%
REVB - GNPX
48%
Loosely correlated
+0.49%
XERS - GNPX
30%
Poorly correlated
-0.15%
ENVB - GNPX
30%
Poorly correlated
+2.05%
More